BioCentury
ARTICLE | Financial News

6 Dimensions leads Lyvgen's $30M series B

July 20, 2018 4:57 PM UTC

Lyvgen Biopharma Co. Ltd. (Shanghai, China) raised $30 million in a series B round led by 6 Dimensions Capital. New investors Winfair Global and Runling Capital and existing investor Morningside Ventures also participated.

Lyvgen is developing immuno-oncology candidates using its crosslink antibody platform which activates specific receptors in the tumor microenvironment while reducing immune-mediated adverse effects in healthy tissue...